Immunogen (IMGN) call put ratio 22 calls to 1 put into AbbVie (ABBV) to acquire
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) December call option implied volatility is at 106, January is at 112; compared to its 52-week range of 50 to 217 into AbbVie (ABBV) to acquire ImmunoGen for $31.26 per share in cash. Call put ratio 22 calls to 1 put with focus on December 17 and January 21 calls into the bell.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) call put ratio 1.9 calls to 1 put into quarter results
- Valero Energy (VLO) call ratio 1.1 calls to 1 put into quarter results
- Market Vectors Semiconductor ETF (SMH) call put ratio 1 call to 1.7 puts as share price down 4.4%
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, Definitive Agreement, abbvSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
